1)岡部治弥,崎村正弘.仮称“非特異性多発性小腸潰瘍症”.胃と腸 3:1539-1549, 1968
2)崎村正弘.“非特異性多発性小腸潰瘍症”の臨床的研究—限局性腸炎との異同を中心として.福岡医誌 61:318-340, 1970
3)Matsumoto T, Nakamura S, Esaki M, et al. Endoscopic features of chronic nonspecific multiple ulcers of the small intestine:comparison with nonsteroidal anti-inflammatory drug-induced enteropathy. Dig Dis Sci 51:1357-1363, 2006
4)Esaki M, Umeno J, Kitazono T, et al. Clinicopathologic features of chronic nonspecific multiple ulcers of the small intestine. Clin J Gastroenterol 8:57-62, 2015
5)Umeno J, Hisamatsu T, Esaki M, et al. A hereditary enteropathy caused by mutations in the SLCO2A1 Gene, encoding a prostaglandin transporter. PLoS Genet 11:e1005581, 2015
6)日比紀文(研究代表者).「腸管希少難病群の疫学,病態,診断,治療の相同性と相違性から見た包括的研究」平成25年度研究報告書.厚生労働科学研究費補助金難治性疾患等克服研究事業,2014
7)梅野淳嗣,江﨑幹宏,平野敦士,他.非特異性多発性小腸潰瘍症/CEASの臨床像と鑑別診断.胃と腸 52:1411-1422, 2017
8)Matsumoto T, Iida M, Matsui T, et al. Chronic nonspecific multiple ulcers of the small intestine:a proposal of the entity from Japanese gastroenterologists to Western enteroscopists. Gastrointest Endosc 66:99-107, 2007
9)Umeno J, Esaki M, Hirano A, et al. Clinical features of chronic enteropathy associated with SLCO2A1 gene:a new entity clinically distinct from Crohn's disease. J Gastroenterol 53:907-915, 2018
10)Hosoe N, Ohmiya N, Hirai F, et al. Chronic enteropathy associated with SLCO2A1 gene[CEAS]-Characterisation of an enteric disorder to be considered in the differential diagnosis of Crohn's disease. J Crohns Colitis 11:1277-1281, 2017
11)河内修司,蔵原晃一,川崎啓祐,他.ダブルバルーン小腸内視鏡にて病変を観察しえた非特異性多発性小腸潰瘍症の1例.胃と腸 49:1318-1325, 2014
12)八尾恒良,岩下明德,平橋美奈子,他.臨床病理学的所見からみた非特異性多発性小腸潰瘍症—慢性出血性小腸潰瘍症.胃と腸 50:917-931, 2015
13)梅野淳嗣,江﨑幹宏,河内修司,他.ばち指と皮膚肥厚所見を呈した非特異性多発性小腸潰瘍症の2例.胃と腸 51:1069-1076, 2016
14)田邉寛,岩下明德.非特異性多発性小腸潰瘍症/CEASの臨床病理学的特徴と鑑別疾患.胃と腸 52:1431-1439,2017
15)Uppal S, Diggle CP, Carr IM, et al. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet 40:789-793, 2008
16)Zhang Z, Xia W, He J, et al. Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy. Am J Hum Genet 90:125-132, 2012
17)新関寛徳.非特異性多発性小腸潰瘍症/CEASの消化管外病変—肥厚性皮膚骨膜症.胃と腸 52:1445-1452, 2017
18)石ヶ坪良明.腸管ベーチェット病診療ガイドライン平成21年度案—コンセンサス・ステートメントに基づく.石ヶ坪良明(研究代表者).ベーチェット病に関する調査研究.厚生労働省科学研究費補助金難治性疾患克服研究事業,2010
19)Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease:indication of anti-TNFα monoclonal antibodies. J Gastroenterol 49:156-162, 2014
20)蔵原晃一,河内修司,川崎啓祐,他.小腸潰瘍の鑑別診断—X線診断を中心に.胃と腸 49:1267-1281, 2014
21)鳥巣剛弘,岡本康治,鷲尾恵万,他.NSAIDs・LDA起因性下部消化管粘膜傷害の病態と内視鏡診断.胃と腸 51:442-449, 2016
22)Matsumoto T, Kudo T, Esaki M, et al. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy:a Japanese multicenter study. Scand J Gastroenterol 43:490-496, 2008
23)池田圭祐,岩下明德,田邉寛,他.NSAID起因性小腸病変の病理組織学的特徴と鑑別診断.胃と腸 46:137-143, 2011
24)八尾隆史,蔵原晃一,大城由美,他.非ステロイド系抗炎症剤(NSAID)起因性腸病変の臨床病理学的特徴と病態.胃と腸 42:1691-1700, 2007
25)松本主之,梅野淳嗣,江﨑幹宏,他.非特異性多発性小腸潰瘍症/CEASとプロスタグランジン腸症.胃と腸 52:1406-1410, 2017